The ALKBH2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of the human lung adenocarcinoma cell line A-549 with disruption of the ALKBH2 gene. This loss-of-function model facilitates study of ALKBH2-dependent DNA repair. The polyclonal nature yields heterogeneous gene disruptions, suitable for pooled functional screens, bulk assays, and population-level analyses without requiring clonal isolation. CRISPR/Cas9 editing preserves the biological context of the host line.
The A-549 cell line was originally derived from the lung tissue of a 58-year-old Caucasian male with lung carcinoma and exhibits an adherent epithelial morphology. A-549 cells are widely employed in cancer research as a model for lung adenocarcinoma, particularly for studies of oncogenic signaling, drug response, and metastasis. Their well-characterized growth properties and genomic features make them a robust platform for investigating DNA repair mechanisms and chemoresistance pathways. This knockout model leverages the A-549 background to interrogate the specific contributions of ALKBH2 to DNA damage responses in a clinically relevant setting.
ALKBH2 is an iron- and 2-oxoglutarate-dependent dioxygenase that reverses DNA alkylation damage by demethylating 1-methyladenine and 3-methylcytosine. This protects genome integrity by preventing mutagenic and cytotoxic lesions. ALKBH2 is recruited to replication foci by PCNA and cooperates with APE1 and XRCC1 in base excision repair. Transcription is controlled by TP53, SP1, and E2F1. Downstream, ALKBH2 activity reduces mutation frequency and enhances cell survival after alkylation damage, influencing chemoresistance.
In the A-549 lung adenocarcinoma model, ALKBH2 knockout provides a powerful tool to dissect the role of direct DNA alkylation repair in tumor cell biology. Given that A-549 cells are frequently employed in studies of chemotherapeutic resistance, loss of ALKBH2 may sensitize these cells to alkylating drugs such as temozolomide and cisplatin, making this model invaluable for investigations of drug response mechanisms and synthetic lethality. Moreover, the interplay between ALKBH2 and other DNA damage response pathways, including base excision repair and cell cycle checkpoints, can be examined to understand how cancer cells cope with genotoxic stress and maintain genomic stability.
This polyclonal knockout population is well-suited for investigating DNA alkylation damage repair, chemosensitivity to alkylating agents such as temozolomide and cisplatin, genome stability, and synthetic lethality interactions. Knockout validation can be performed by Western blot and RT-qPCR, while DNA damage responses are assessed by comet assay and ??H2AX immunofluorescence. Functional studies employ colony formation assays with alkylating drugs, and downstream molecular analyses may include RNA-seq and cell cycle analysis. For additional product information or to place an order, please contact Ascent Research.
